| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Jubilant Pharmova Limited (NSE: JUBLPHARMA)
JUBLPHARMA Technical Analysis
5
| As on 30th Apr 2024 JUBLPHARMA SHARE Price closed @ 674.20 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 478.79 & Strong Buy for SHORT-TERM with Stoploss of 604.70 we also expect STOCK to react on Following IMPORTANT LEVELS. |
JUBLPHARMASHARE Price
| Open | 688.00 | Change | Price | % |
| High | 688.05 | 1 Day | -11.70 | -1.71 |
| Low | 664.45 | 1 Week | -11.10 | -1.62 |
| Close | 674.20 | 1 Month | 104.30 | 18.30 |
| Volume | 177612 | 1 Year | 362.45 | 116.26 |
| 52 Week High 483.65 | 52 Week Low 271.85 | ||||
NSE INDIA Most Active Stocks
| IDEA | 13.20 | -1.86% |
| YESBANK | 26.15 | -3.51% |
| NHPC | 96.20 | 3.00% |
| PNB | 141.05 | 2.77% |
| IDFCFIRSTB | 82.15 | 0.61% |
| RECLTD | 507.15 | 9.54% |
| IOC | 168.85 | -4.47% |
| MAHABANK | 70.10 | -1.34% |
| HFCL | 100.50 | 2.60% |
| TATASTEEL | 165.00 | -1.43% |
NSE INDIA Top Gainers Stocks
| HISARMETAL | 222.00 | 20.00% |
| WILLAMAGOR | 40.95 | 19.91% |
| NGIL | 61.65 | 15.67% |
| LIKHITHA | 351.20 | 12.80% |
| COMPUSOFT | 36.45 | 11.98% |
| PDMJEPAPER | 83.50 | 11.71% |
| BFUTILITIE | 862.25 | 10.74% |
| POWERINDIA | 9578.75 | 10.53% |
| IRIS | 155.15 | 10.00% |
| HINDMOTORS | 34.65 | 10.00% |
NSE INDIA Top Losers Stocks
| JUBLPHARMA Daily Charts |
JUBLPHARMA Intraday Charts |
Whats New @ Bazaartrend |
JUBLPHARMA Free Analysis |
|
|
JUBLPHARMA Important Levels Intraday
| RESISTANCE | 719.68 |
| RESISTANCE | 705.09 |
| RESISTANCE | 696.08 |
| RESISTANCE | 687.06 |
| SUPPORT | 661.34 |
| SUPPORT | 652.32 |
| SUPPORT | 643.31 |
| SUPPORT | 628.72 |
JUBLPHARMA Target April 2024
| 4th UP Target | 757.24 |
| 3rd UP Target | 698.35 |
| 2nd UP Target | 661.94 |
| 1st UP Target | 625.54 |
| 1st DOWN Target | 521.66 |
| 2nd DOWN Target | 485.26 |
| 3rd DOWN Target | 448.85 |
| 4th DOWN Target | 389.96 |
JUBLPHARMA Weekly Target
| 4th UP Target | 768.52 |
| 3rd UP Target | 740.34 |
| 2nd UP Target | 722.92 |
| 1st UP Target | 705.50 |
| 1st DOWN Target | 655.80 |
| 2nd DOWN Target | 638.38 |
| 3rd DOWN Target | 620.96 |
| 4th DOWN Target | 592.78 |
JUBLPHARMA Target2024
| 4th UP Target | 1088.67 |
| 3rd UP Target | 914.46 |
| 2nd UP Target | 806.77 |
| 1st UP Target | 699.09 |
| 1st DOWN Target | 391.81 |
| 2nd DOWN Target | 284.13 |
| 3rd DOWN Target | 176.44 |
| 4th DOWN Target | 2.23 |
Jubilant Pharmova Limited ( NSE INDIA Symbol : JUBLPHARMA )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
JUBLPHARMA Synopsis Technicals View
| 50 Day EMA |
N/A (Short Term) |
N/A | |
| 100 Day EMA | N/A (Mid Term) | N/A | |
| 200 Day EMA | N/A (Long Term) | N/A | |
| MACD (12 26 9) | N/A | N/A | |
| RSI (14) | N/A | N/A | |
| MFI (14) | N/A | N/A | |
| CCI (20) | N/A | N/A | |
| WILLIAM %R (14) | N/A | N/A | |
| ADX (14) | N/A | N/A | |
| PSAR | N/A | N/A | |
| 10 Day Avg Volume | N/A | ||
JUBLPHARMA Other Details
| Segment | EQ | |
| Market Capital | 97127972864.00 | |
| Sector | Healthcare | |
| Industry | Drug Manufacturers-Specialty & Generic | |
| Offical website | > | |
JUBLPHARMA Address
 |
||
JUBLPHARMA Latest News
JUBLPHARMA Business Profile
Jubilant Pharmova Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Pharmaceuticals; Contract Research & Development Services; and Proprietary Novel Drugs. The Pharmaceuticals segment engages in the manufacturing and supply of allergy therapy products, contract manufacturing of sterile injectables and non-sterile products, active pharmaceutical ingredients, and solid dosage formulations, as well as sale of radiopharmaceuticals through a network of 48 radio pharmacies in the United States. The Contract Research & Development Services segment provides collaborative research services to pharmaceutical innovators. The Proprietary Novel Drugs segment develops therapies in the areas of oncology and auto-immune disorders. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is headquartered in Noida, India. Address: 1A, Sector 16A, Noida, India, 201301
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service